Yang, Q, Chen, H, Correa, A, Devine, O, Mathews, TJ, Honein, MA. Racial differences in infant mortality attributable to birth defects in the United States, 1989–2002. Birth Defects Res A Clin Mol Teratology 2006; 76: 706–713.
Kogon, B, Jain, A, Oster, M, Woodall, K, Kanter, K, Kirshbom, P. Risk factors associated with readmission after pediatric cardiothoracic surgery. Ann Thorac Surg 2012; 94: 865–873.
Dabal, RJ, Kirklin, JK, Kukreja, M, et al. The modern Fontan operation shows no increase in mortality out to 20 years: a new paradigm. J Thorac Cardiovasc Surg 2014; 148: 2517–2523. e2511.
Knowles, RL, Bull, C, Wren, C, Dezateux, C. Mortality with congenital heart defects in England and Wales, 1959–2009: exploring technological change through period and birth cohort analysis. Arch Dis Child 2012; 97: 861–865.
Mackie, AS, Gauvreau, K, Newburger, JW, Mayer, JE, Erickson, LC. Risk factors for readmission after neonatal cardiac surgery. Ann Thorac Surg. 2004; 78: 1972–1978; discussion 1978.
Kansagara, D, Englander, H, Salanitro, A, et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011; 306: 1688–1698.
Tregay, J, Wray, J, Bull, C, et al. Unexpected deaths and unplanned re-admissions in infants discharged home after cardiac surgery: a systematic review of potential risk factors. Cardiol Young. 2015; 25: 839–852.
Polineni, S, Parker, DM, Alam, SS, et al. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and N-terminal prohormone of brain natriuretic peptide before cardiac surgery. J Am Heart Assoc 2018; 7: 14.
Gaggin, HK, Januzzi, JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta Mol Basis Dis 2013; 1832: 2442–2450.
Fernandes, BA, Maher, KO, Deshpande, SR. Cardiac biomarkers in pediatric heart disease: a state of art review. World J cardiol 2016; 8: 719–727.
Mathews, LR, Lott, JM, Isse, K, et al. Elevated ST2 distinguishes incidences of pediatric heart and small bowel transplant rejection. American J Transplant 2016; 16: 938–950.
Chida, A, Sato, H, Shintani, M, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension. Circ J 2014; 78: 436–442.
Yang, Z, Wang, KKW. Glial Fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 2015; 38: 364–374.
Dumic, J, Dabelic, S, Flogel, M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616–635.
Opotowsky, AR, Baraona, F, Owumi, J, et al. Galectin-3 is elevated and associated with adverse outcomes in patients with single-ventricle fontan circulation. J Am Heart Assoc 2016; 5: 1.
Magruder, JT, Hibino, N, Collica, S, et al. Association of nadir oxygen delivery on cardiopulmonary bypass with serum glial fibrillary acid protein levels in paediatric heart surgery patients. Interact Cardiovasc Thorac Surg 2016; 23: 531–537.
Vedovelli, L, Padalino, M, Simonato, M, et al. Cardiopulmonary bypass increases plasma glial fibrillary acidic protein only in first stage palliation of hypoplastic left heart syndrome. Can J Cardiol 2016; 32: 355–361.
Vedovelli, L, Padalino, M, D’Aronco, S, et al. Glial fibrillary acidic protein plasma levels are correlated with degree of hypothermia during cardiopulmonary bypass in congenital heart disease surgery. Interact Cardiovasc Thorac Surg 2017; 24: 436–442.
Bembea, MM, Savage, W, Strouse, JJ, et al. Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation. Pediatr Crit Care Med 2011; 12: 572–579.
Stewart, A, Tekes, A, Huisman, TA, et al. Glial fibrillary acidic protein as a biomarker for periventricular white matter injury. Am J Obstet Gynecol 2013; 209: 27.e21–27.
Brunetti, MA, Jennings, JM, Easley, RB, et al. Glial fibrillary acidic protein in children with congenital heart disease undergoing cardiopulmonary bypass. Cardiol Young 2014; 24: 623–631.
Hori, D, Ono, M, Rappold, TE, et al. Hypotension after cardiac operations based on autoregulation monitoring leads to brain cellular injury. Ann Thorac Surg 2015; 100: 487–493.
Hori, D, Everett, AD, Lee, JK, et al. Rewarming rate during cardiopulmonary bypass is associated with release of glial fibrillary acidic protein. Ann Thorac Surg 2015; 100: 1353–1358.
Ennen, CS, Huisman, TA, Savage, WJ, et al. Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole-body cooling. Am J Obstet Gynecol 2011; 205: 251.e251–257.
Brown, JR, Jacobs, JP, Alam, SS, et al. Utility of biomarkers to improve prediction of readmission or mortality after cardiac surgery. Ann Thorac Surg 2018; 106: 1294–1301.
O’Brien, SM, Jacobs, JP, Pasquali, SK, et al. The society of thoracic surgeons congenital heart surgery database mortality risk model: part 1-statistical methodology. Ann Thorac Surg 2015; 100: 1054–1062.
Hajian-Tilaki, K. Receiver Operating Characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med 2013; 4: 627–635.
Cook, NR, Ridker, PM. The use and magnitude of reclassification measures for individual predictors of global cardiovascular risk. Ann Intern Med 2009; 150: 795–802.
Pencina, MJ, D’Agostino, RB, Pencina, KM, Janssens, ACJW, Greenland, P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176: 473–481.
Cook, NR, Paynter, NP. Performance of reclassification statistics in comparing risk prediction models. Biom J 2011; 53: 237–258.
Hanley, JA, McNeil, BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.
Efron, B, Tibshirani, R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986; 1: 54–75.
Meeusen, JW, Johnson, JN, Gray, A, et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem 2015; 48: 1337–1340.
Tang, WH, Shrestha, K, Shao, Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385–390.
Rehman, SU, Mueller, T, Januzzi, JL
, Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52: 1458–1465.
Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810–1852.
Mohammed, LA, Gafar, H.S., Hussien, N.R. Galectin-3 as early detector of heart failure in children with congenital acyanotic heart disease. Clin Med Diagn 2014; 4: 90–98.
Goldman, J, Becker, ML, Jones, B, Clements, M, Leeder, JS. Development of biomarkers to optimize pediatric patient management: what makes children different?. Biomark Med 2011; 5: 781–794.
Cantinotti, M, Passino, C, Storti, S, Ripoli, A, Zyw, L, Clerico, A. Clinical relevance of time course of BNP levels in neonates with congenital heart diseases. Clin Chim Acta 2011; 412: 2300–2304.
Holmgren, D, Westerlind, A, Lundberg, PA, Wahlander, H. Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload. Clin physiol Funct Imaging 2005; 25: 263–269.
Chave, M, Marques-Vidal, P. Factors associated with readmission of patients with congenital heart disease in a Swiss University Hospital. Pediatr cardiol 2017; 38: 650–655.
Crowe, S, Ridout, DA, Knowles, R, et al. Death and emergency readmission of infants discharged after interventions for congenital heart disease: a national study of 7643 infants to inform service improvement. J Am Heart Assoc 2016; 5: 5.
Kogon, B, Woodall, K, Kanter, K, Alsoufi, B, Oster, M. Reducing readmissions following paediatric cardiothoracic surgery: a quality improvement initiative. Cardiol Young 2015; 25: 935–940.
Vo, D, Zurakowski, D, Faraoni, D. Incidence and predictors of 30-day postoperative readmission in children. Paediatr Anaesth 2018; 28: 63–70.
Lawley, CM, Lain, SJ, Figtree, GA, Sholler, GF, Winlaw, DS, Roberts, CL. Mortality, rehospitalizations and costs in children undergoing a cardiac procedure in their first year of life in New South Wales, Australia. Int J Cardiol 2017; 241: 156–162.
Parker, DM, Everett, AD, Stabler, ME, et al. Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery. J Card Surg 2019; 34: 329–336.
Parker, DM, Everett, AD, Stabler, ME, et al. The Association between Cardiac Biomarker NT-proBNP and 30-day Readmission or Mortality after Pediatric Congenital Heart Surgery. World J Pediatr Congenit Heart Surg 2019; Accepted March 6, 2019.
Parker, DM, Everett, AD, Stabler, ME, et al. Novel Biomarkers Improves Prediction of 365-day Readmission after Pediatric Congenital Heart Surgery. ATS 2019; Accepted May 21, 2019.
Turley, K, Tyndall, M, Roge, C, et al. Critical pathway methodology: effectiveness in congenital heart surgery. Ann Thorac Surg 1994; 58: 57–63; discussion 63–55.
Williams, DL, Gelijns, AC, Moskowitz, AJ, et al. Hypoplastic left heart syndrome: valuing the survival. J Thorac Cardiovasc Surg 2000; 119: 720–731.
Jacobs, JP, Jacobs, ML, Maruszewski, B, et al. Initial application in the EACTS and STS Congenital Heart Surgery Databases of an empirically derived methodology of complexity adjustment to evaluate surgical case mix and results. Eur J cardiothorac Surg 2012; 42: 775–779; discussion 779–780.